Lusine Hovhannisyan, Co-Founder of ArmBionics, Assistant Doctor at Insel Group, shared a post on LinkedIn:
“Taking courses and improving the fundamental understanding in radiation oncology is a mandatory part for specialization. ESTRO courses are highly valued for this purpose and many radiation oncologists in training are choosing them as a part of their education program. One good course is the course on IGRT and adaptive radiotherapy. Around 100 participants from different countries (not only Europe) joined this year’s course. Some interesting highlights from the course:
1. Ongoing trial for pancreatic cancer NRG-GI 011 ‘ Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)’ which will evaluate dose escalation versus standard dose.
2. In meta-analysis by Nikitas et al. (Lacet Oncology, 2025) it was demonstrated that acute GI and GU toxicities prostate cancer patients receiving radiotherapy were correlated with late toxicities.
3. The results of the Phase 2 RAIDER Randomised Controlled Trial Dose-escalated Adaptive Radiotherapy for Bladder Cancer showed acceptable safety profile.”
Title: The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
Authors: John Nikitas, Parsa Jamshidian, Alison C Tree, Emma Hall, David Dearnaley, Jeff M Michalski, W Robert Lee, Paul L Nguyen, Howard M Sandler, Charles N Catton, Himanshu R Lukka, Luca Incrocci, Wilma Heemsbergen, Floris J Pos, Soumyajit Roy, Shawn Malone, Eric Horwitz, Jessica Karen Wong, Stefano Arcangeli, Giuseppe Sanguineti, Tahmineh Romero, Yilun Sun, Michael L Steinberg, Luca F Valle, Joanne B Weidhaas, Daniel Spratt, Donatello Telesca, Amar U Kishan
Read further on PubMed.
More posts featuring Radiation Oncology on OncoDaily.